Labcorp Supports Multi-Institution Trial to Expand Genetic Testing in Colorectal Cancer
Rhea-AI Summary
Labcorp (NYSE: LH) is collaborating with the Alliance for Clinical Trials in Oncology on a national, multicenter trial for newly diagnosed colorectal cancer patients. The NCI-sponsored study will test proactive outreach to increase cascade germline genetic testing in at-risk relatives and evaluate multigene panel testing’s impact on care, with Labcorp as exclusive genetic testing provider using its Invitae platform.
AI-generated analysis. Not financial advice.
Positive
- Exclusive genetic testing provider for NCI-sponsored national colorectal cancer trial
- Collaboration with Alliance for Clinical Trials in Oncology and NCI network sites
- Trial aims to increase cascade testing among at-risk first-degree relatives
- Nationwide enrollment of patients and relatives, including sites in Puerto Rico
Negative
- None.
Key Figures
Market Reality Check
Peers on Argus
LH gained 1.74% with modestly above-average volume, while key diagnostics peers like DGX and NTRA also traded higher. However, no peers appeared in the momentum scanner and sector_momentum_context flags this as stock-specific rather than a broad sector move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| May 27 | Conference appearance | Neutral | -0.1% | Announcement of presentation at 2026 Jefferies Global Healthcare Conference. |
| May 20 | Product launch | Positive | +0.6% | Launch of MyLabcorp™ AI-powered app to help consumers interpret lab results. |
| May 12 | Tech collaboration | Positive | +0.9% | Expanded Epic collaboration to offer full Labcorp test menu via Aura platform. |
| May 01 | Corporate update | Neutral | -0.4% | Knoa Pharma public health–focused operations launch noted alongside Labcorp news flow. |
| Apr 30 | Earnings & guidance | Positive | -0.1% | Q1 2026 beat with revenue $3.54B, EPS growth and raised 2026 guidance. |
Recent operational and collaboration news has generally seen mild positive alignment, while the strong Q1 earnings/raised guidance event showed a slight negative divergence.
Over the past two months, Labcorp has reported several strategic updates, including an expanded Epic integration, launch of the AI-powered MyLabcorp™ app, and solid Q1 2026 results with raised full-year guidance. These were accompanied by conference participation and routine corporate governance filings. Price reactions have mostly been small and aligned with neutral-to-positive news, except for the earnings event on Apr 30, where good results coincided with a slight negative move, suggesting a tempered market response to strong fundamentals.
Market Pulse Summary
This announcement highlights Labcorp’s support of a national colorectal cancer trial assessing germline and cascade genetic testing, with Labcorp as the exclusive provider using its Invitae platform. It builds on prior updates around AI-enabled tools and expanded health-system integrations, reinforcing a strategy centered on advanced diagnostics and oncology. Investors may track enrollment progress, real-world evidence outputs, and how broader multigene panel use could intersect with Labcorp’s existing oncology testing and prior growth in Diagnostics and Biopharma segments.
Key Terms
lynch syndrome medical
National Cancer Institute regulatory
AI-generated analysis. Not financial advice.
Collaborative trial with Alliance for Clinical Trials in Oncology will evaluate new approaches to increase germline genetic testing among at-risk family members
Research will also assess the clinical impact of broader genetic testing in colorectal cancer care
Inherited genetic variants contribute to approximately
The trial will assess whether proactive outreach by healthcare providers, rather than relying on patients to communicate genetic risk to their relatives, can improve participation of first-degree relatives in cascade genetic testing. In parallel, the trial will assess the impact of multigene panel testing on care for patients newly diagnosed with colorectal cancer.
"Genetic testing is a critical tool for identifying inherited cancer risk and guiding care for patients and their families, but too often at-risk relatives are not getting tested," said Shakti Ramkissoon, M.D., Ph.D., vice president, medical lead for oncology at Labcorp. "By supporting this trial and serving as the exclusive genetic testing provider, Labcorp is helping generate real-world evidence on how healthcare providers can connect families to genetic testing and follow-up care."
The trial is sponsored by the National Cancer Institute (NCI), part of the National Institutes of Health, and led and conducted by the Alliance for Clinical Trials in Oncology. It includes participation from the NCI National Clinical Trials Network, which comprises academic medical centers, community oncology health systems and NCI-designated cancer centers. The study is expected to enroll patients and their relatives nationwide, including sites in
"By involving cancer care providers across our network, this study aims to evaluate a practical approach that can strengthen genetic risk identification for patients and their families," noted Frank A. Sinicrope, MD, from the Mayo Clinic and Heather Hampel, MS, CGC, from City of Hope, who are co-lead investigators for the trial. "The findings have the potential to help shape how genetic testing results are communicated to at-risk relatives in patients with colorectal cancer who have hereditary cancer syndromes nationwide."
This collaboration reflects Labcorp's continued commitment to advancing genetics-based approaches to improve outcomes for patients with cancer, while supporting high-impact clinical research in collaboration with leading research organizations.
For more information on the clinical trial, visit https://clinicaltrials.gov/study/NCT07143487 or view Alliance A212101 at https://www.allianceforclinicaltrialsinoncology.org/main/public/standard.xhtml?path=%2FPublic%2FFeatured-Trials
To learn more about Labcorp's hereditary cancer panels, visit https://www.invitae.com/us/providers/oncology/personalize-cancer-treatment
About Labcorp
Labcorp (NYSE: LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. We provide insights and advance science to improve health and improve lives through our unparalleled diagnostics and drug development laboratory capabilities. The company's nearly 71,000 employees serve clients in approximately 100 countries, provided support for more than
View original content to download multimedia:https://www.prnewswire.com/news-releases/labcorp-supports-multi-institution-trial-to-expand-genetic-testing-in-colorectal-cancer-302785036.html
SOURCE Labcorp